Keeper Security Delivers Structured Governance for Humans and AI Agents with New PAM Approval Workflows in KeeperPAM
Integrated Quantum Launches $10K Kaggle Hackathon to ‘Pierce the VEIL’
CleanStart Launches Cleansight To Uncover Hidden Container Risk And Map Vulnerabilities To Trusted Replacement Images
72% of homeowners plan to stay put as aging homes drive repair-focused spending, Housecall Pro report finds
Quest Software Extends Data and AI Leadership with Quest Data Modeler and Quest Data Intelligence, Enhancing its Trusted Data Management Platform
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients…
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models…
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in…
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1…
“Austin Accident Lawyer” Andrew Traub shares how his firm has helped their clients get past…
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…